20.2.1
Hemodialysis
Patients undergoing facility-based hemodialysis may have multiple cardiovascular and diabetic comorbidities. In assessing their fitness to drive, physicians should evaluate these patients individually for the presence of relevant comorbidities, medications, and adverse symptoms associated with their treatments.
Few studies provide clinicians with validated tools to identify dialysis patients who may not be fit to drive. A study of 186 patients receiving dialysis in the United States (89% hemodialysis, 11% peritoneal dialysis) revealed that 40% of surveyed patients were “not comfortable driving” (Vats and Duffy, 2010). However, 42% of this group continued to drive, with 48% of those reporting crashes. Approximately three-quarters of patients who admitted to feeling uncomfortable driving reported one or more symptoms of weakness, dizziness, or difficulty with coordination after a hemodialysis session.
Varela et al. (2015) analyzed the accuracy of an instrument developed by the American Automobile Association and the American Medical Association to assess the safety of geriatric drivers, as applied specifically to 106 dialysis patients (68% hemodialysis, 32% peritoneal dialysis). The “Am I a Safe Driver?” checklist asks patients to answer 24 specific questions (one of which was omitted for the dialysis patients). The authors concluded that answering “yes” to two or more questions on the checklist was potentially useful for identifying patients at high risk for driving impairment (84% sensitivity, 58% specificity), but confirmation by other methods was required, as nearly half of “screen-positive” patients might still be considered safe to drive.
These studies suggest that (1) a substantial proportion of patients receiving dialysis (especially hemodialysis) may have episodes when they are not fit to drive, especially after dialysis sessions; and (2) a checklist such as “Drivers 65 Plus: Check Your Performance” (AAA Foundation for Traffic Safety, 2019) may be useful for identifying patients who require further evaluation. However, the data are insufficient to mandate regular screening of dialysis patients with this instrument or available alternatives.
Dialysis staff may consider asking patients how they plan to return home in the event of a highly symptomatic hemodialysis session and discussing alternative arrangements for patients who had planned to drive but do not appear well enough to do so.
Hemodialysis patients should not drive further than one or two days’ distance from their home without making arrangements for dialysis at another centre. If a longer road trip is planned, such patients should consult with their local dialysis unit, which will have access to lists of dialysis centres in Canada and the United States that will accept travelling patients. The patient’s overall health and stability on dialysis should be evaluated by their attending nephrologist before any travel plans are made.